If you're building a Canadian market entry strategy around today's Medical Device Establishment Licence (MDEL) rules, you're planning against a regulation that's about to change. Health Canada finalized Phase 2 of its MDEL modernization on June 17, 2026, publishing the amended regulations (SOR/2026-110) in the Canada Gazette, Part II. They come into force December 14, 2026 — 180 days after publication.
This isn't a minor housekeeping update. It changes who needs an MDEL at all, what MDEL holders are required to track, and how "documented procedures" gets enforced. Here's what's actually in it.
1. Foreign Distributors Gain an Exemption Manufacturers Already Had
Foreign manufacturers already have this exemption today — it isn't new. Under section 44(4) of the Medical Devices Regulations, a foreign manufacturer selling through a Canadian importer that holds a valid MDEL does not need an MDEL of its own. This has been the rule before Phase 2 and continues unchanged after December 14, 2026.
Foreign distributors did not have that exemption. Under the current rules, a foreign distributor (a company selling a device it did not manufacture) generally needs its own MDEL, even when a Canadian importer is already involved. Phase 2 changes this: from December 14, 2026, a foreign distributor selling exclusively through a Canadian importer that already holds a valid MDEL will no longer need an MDEL of its own.
In short: Phase 2 extends an exemption that manufacturers already had to distributors—it does not eliminate the need for an MDEL somewhere in the chain. The Canadian importer's licence still has to cover the activity; what changes is who else in the chain is required to also hold one.
A practical wrinkle: if the device is Class II, III, or IV, the manufacturer still needs a valid Health Canada Medical Device Licence (MDL) for the product itself—the MDL and the MDEL are separate authorizations, and the manufacturer exemption from holding an MDEL doesn't remove the need for an MDL where the device class requires one. Class I devices don't require an MDL, but the importer still needs an MDEL covering the import activity.
2. Supplier List Disclosure Becomes Mandatory
Starting December 14, 2026, MDEL applicants and holders must provide a list of the suppliers for the devices they import or distribute—both at initial application and at each licence review (ALR). This is a traceability measure: Health Canada wants visibility into who is supplying devices moving through Canadian commerce, not just who holds the licence.
For companies working with an MDEL-holding partner, this means your supplier information now needs to be complete, current, and ready to hand over on a recurring basis — not just a one-time disclosure at onboarding..
3. The Documented Procedures Requirement Is Being Clarified, Not Introduced
MDEL holders have long been expected to have documented procedures in place for their regulated activities. Phase 2 makes this an explicit legal requirement rather than an implied or attestation-based expectation.
This distinction matters. Companies that assumed their existing SOPs already satisfied Health Canada's
expectations are the ones most likely to be caught off guard here — the obligation isn't new, but the bar for
demonstrating compliance with it is about to be more clearly defined and enforced.
A Note on GUI-0016
Health Canada has published an updated version of GUI-0016, its guidance document on medical device establishment licensing, reflecting these Phase 2 changes. Important: this updated guidance does not take effect until December 14, 2026. Anyone consulting GUI-0016 before that date is reading a version of the guidance that isn't yet operative. Until then, the current version remains the applicable reference.
What This Means If You're Entering Canada Now
If you're a foreign medical device manufacturer or distributor building your Canadian go-to-market plan between now and December 2026, a few practical takeaways:
- Confirm whether you're selling as the manufacturer or as a distributor of someone else's device — the two are on different timelines for this exemption, and the distinction determines whether you already qualify or have to wait until December 14, 2026.
- If your strategy relies on a Canadian importer of record, confirm the importer's MDEL genuinely covers the import activity for your device's class.
- For Class II, III, or IV devices, remember the MDL (product licence) requirement sits alongside the MDEL question, not instead of it.
- Start organizing supplier information early — the annual review requirement means this becomes a recurring compliance task, not a one-time form.
- Don't assume existing SOPs are sufficient. Review documented procedures against the amended regulatory text, not just the current guidance.
- Track which version of GUI-0016 you're referencing, and confirm the effective date before relying on it for a submission or audit.
Getting the Timing Right
Regulatory transition windows like this one reward manufacturers and distributors who plan ahead of the in-force date rather than reacting to it. Whether you're structuring a new MDEL-based partnership or reassessing an existing one, understanding exactly what changes on December 14, 2026 — and what doesn't — is the difference between a smooth transition and a compliance scramble.
How Globyz Can Help
Globyz BioPharma Services holds an MDEL and provides licensed import, distribution, and 3PL support for medical device manufacturers and distributors entering the Canadian market. We're tracking the Phase 2 amendments closely and can help you assess how they affect your supply chain structure ahead of the December 2026 deadline.
Have questions about how these changes affect your Canadian market entry plan? Contact us to talk it through.
